309 The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial

Registros relacionados

• Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
  por: Nelson S Moss, et al.
  Publicado em: (2022-09-01)
• Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
  por: Ribas Antoni, et al.
  Publicado em: (2012-11-01)
• Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
  por: Emanuela Ferraro, et al.
  Publicado em: (2022-03-01)
• Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras
  por: Karam Irene, et al.
  Publicado em: (2013-01-01)
• A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
  por: Philip Friedlander, et al.
  Publicado em: (2018-09-01)